IMMX — Immix Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1873835 ·
Last close
$9.29
Market Cap
$664.60M
52W High
$15.10
52W Low
$2.31
ADV30
1,633,502
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,456,343 | -11,557,002 | 239,108,896 | 225,491,985 | 10,192,343 |
| Mar 2026 | 0 | — | -10,803,855 | -10,086,687 | 95,816,057 | 79,250,163 | 11,452,001 |
| Dec 2025 | 0 | — | -10,893,276 | -10,687,830 | 104,840,341 | 93,928,566 | 11,044,171 |
| Sep 2025 | 0 | — | -7,662,509 | -7,585,692 | 20,080,604 | 15,947,308 | 11,815,634 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-32,072,357
Investing CF
$-11,946,908
Financing CF
$107,349,298
CapEx
$-697,698
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.79
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-114,549,971
Inventory
—
Receivables
$0
ST Investments
$11,328,999
EBIT TTM
$-36,077,345
Pretax Income TTM
$-34,954,870
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -29,956,415 | -29,438,613 | 104,840,341 | 11,044,171 | 93,796,170 | -23,930,304 |
| Dec 2024 | 0 | -22,674,680 | -21,613,376 | 22,947,872 | 9,696,669 | 13,251,203 | -14,595,102 |
| Dec 2023 | 0 | -16,141,113 | -15,426,048 | 19,925,160 | 3,721,783 | 16,405,114 | -11,371,438 |
| Dec 2022 | 0 | -8,218,948 | -8,229,713 | 14,908,101 | 1,748,296 | 13,159,805 | -7,408,303 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,122,475
NetIncome TTM
$-34,982,772
OpCashFlow TTM
—
Assets (Latest)
$95,816,057
Forward EPS
$-0.91
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $9.46 · call oi: 2,711 · put oi: 1,133
Expected Move to 2026-10-16:
±$1.57
(16.65%) —
implied range
$7.89 –
$11.04
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FTH | Faeth Therapeutics, Inc. | $661.77M | $25.61 | — |
| NVCT | Nuvectis Pharma, Inc. | $657.13M | $20.13 | — |
| PHAR | Pharming Group N.V. | $674.52M | $9.53 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $653.22M | $11.00 | — |
| WVE | Wave Life Sciences, Inc. | $683.76M | $3.47 | — |
News headlines (Yahoo Finance, 1h cache)
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
2026-10-05 12:45 · Yahoo
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
2026-10-05 03:02 · Yahoo
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
2026-09-30 21:15 · Yahoo
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
2026-09-29 17:48 · Yahoo
Immix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 Trial
2026-09-29 13:34 · Yahoo
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Po
2026-09-29 11:00 · Yahoo
Straight Out Of A Soap Opera: Biotech Exec Arrested After 21 Years On The Run
2026-07-21 21:17 · Yahoo
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
2026-06-18 13:55 · Yahoo
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
2026-05-27 13:55 · Yahoo
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
2026-05-22 21:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.